TOPARP: Ph. II Trial of Olaparib in Patients with advanced CRPC

TOPARP is an open-label, single arm, two part adaptive design phase II trial of olaparib in mCRPC. Patients will receive single agent olaparib at a dose of 400 mg twice daily, continuously on a 28-day cycle, until objective disease progression or unacceptable toxicity or patient withdrawal for whatever reason.

Networks

  • ICR Clinical Trials & Statistics Unit (ICR-CTSU)

Contact Information

Email:
toparp-icrctsu@icr.ac.uk
Address:

ICR Clinical Trials & Statistics Unit (ICR-CTSU)
The Institute of Cancer Research
15 Cotswold Road
Sutton
Surrey
SM2 5NG
England

Annual Statistics

Year Access Requests Received Access Requests Approved
Internal External Commercial Internal External Commercial
2015 N/A N/A N/A N/A N/A N/A
2016 N/A N/A N/A N/A N/A N/A
2017 N/A N/A N/A N/A N/A N/A
2018 N/A N/A N/A N/A N/A N/A
2019 N/A N/A N/A N/A N/A N/A
2020 N/A N/A N/A N/A N/A N/A
2021 N/A N/A N/A N/A N/A N/A
2022 N/A N/A N/A N/A N/A N/A
2023 N/A N/A N/A N/A N/A N/A
2024 N/A N/A N/A N/A N/A N/A